Instructions for taking Eltrombopag/Eltrombopag: A must-read manual for safely and effectively increasing platelets

Eltrombopag/Eltrombopag (Eltrombopag) is an oral drug used to treat thrombocytopenia. It is mainly suitable for diseases such as idiopathic thrombocytopenia (ITP) and chronic hepatitis C-related ITP. Its mechanism of action is by stimulating megakaryocytes in the bone marrow, thereby promoting the production of platelets. Understanding the correct administration and dosage adjustments is critical to patient efficacy and safety.

Regarding the recommended dosage of eltrombopag, there are different initial dosage regimens for patients of different ages and conditions. In persistent or chronic immune ITP, the recommended initial dose is 25 mg once daily in children 1 to 5 years of age, and 50 mg once daily in adult and pediatric patients 6 years and older. For patients with mild, moderate or severe hepatic impairment, the initial dose should be 25 mg per day or less according to the Child-Pugh classification. For example, when patients of East Asian/Southeast Asian descent are taking eltrombopag, the starting dose can also be 25 mg per day, while for patients with hepatic impairment, it may be necessary to further reduce to 12.5 mg per day. These dose settings are designed to ensure that patients receive optimal efficacy within a safe range.

After starting to take eltrombopag, patients need to monitor their platelet count regularly, with the goal of maintaining the platelet count at≥50×10^9/L to reduce the risk of bleeding. Platelet counts usually increase within 1 to 2 weeks after starting medication and may decrease within 1 to 2 weeks after stopping medication. In addition, the maximum daily dose should not exceed 75 mg. If platelet counts fail to meet criteria to avoid clinically important bleeding after 4 weeks of maximum-dose treatment, your doctor may consider discontinuing the drug.

In patients with chronic hepatitis C-related ITPEltrombopag is also initiated at an initial dose of 25 mg once daily and can be increased by 25 mg every two weeks to achieve target platelet counts required to initiate antiviral therapy. During this phase, patients need to monitor platelet levels weekly to ensure their dose does not exceed 100 mg daily and to promptly discontinue eltrombopag at the end of antiviral treatment.

In addition, in patients with severe aplastic anemia (AA), eltrombopag can be started concurrently with standard immunosuppressive therapy during first-line treatment. In this group of patients, the starting dose is 2.5 mg/kg for pediatric patients 2 to 5 years old, 75 mg for children 6 to 11 years old, and 150 mg for patients 12 years and older, with a typical treatment duration of six months. For patients with severe AA of East or Southeast Asian ancestry or those with liver impairment, the first-line treatment dose may need to be reduced by 50%.

In patients with refractory severe AA, the initial dose is 50 mg once daily, or 25 mg once daily in patients of East/Southeast Asian ancestry or with impaired hepatic function. Subsequently, doctors will adjust the dose by 50 mg every two weeks based on the patient's response to ensure that the final platelet count reaches ≥50×10^9/L. It is worth noting that if no hematological response is seen after 16 weeks of treatment with eltrombopag, or new cytogenetic abnormalities occur, the patient needs to communicate with the doctor in time and consider discontinuing the drug. In addition, eltrombopag should be discontinued if the platelet count is excessively reactive or liver tests are abnormal.

In terms of medication management, patients should pay attention to the time when they take the medication. Eltrombopag should be taken on an empty stomach or with a low calcium meal (≤50 mg). Because certain medications (such as antacids), calcium-rich foods (more than 50 mg of calcium), and supplements containing polyvalent cations (such as iron, calcium, aluminum, magnesium, selenium, zinc) may interfere with the absorption of eltrombopag, patients should avoid concurrent ingestion of these substances at least two hours before or four hours after taking eltrombopag.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7714a0ed-34bb-46e6-a0a5-b363908b22c2